- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LYTIX BIOPHARMA Aktie jetzt für 0€ handeln | |||||
| 01.06. | LYTIX BIOPHARMA ASA: Lytix Biopharma Reports Phase II Data in Melanoma and Triple-Negative Breast Cancer for Ruxotemitide (LTX-315) in Combination with Pembrolizumab | 1 | Cision News | ||
| 21.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma Q1 2026: Clinical Development Priorities On Track as Registrational Path Planning Advances | 2 | Cision News | ||
| 15.05. | LYTIX BIOPHARMA ASA: Lytix Biopharma: Invitation to the Q1 2026 Results Presentation | 1 | Cision News | ||
| 06.05. | LYTIX BIOPHARMA ASA: New Phase II Study Data from Lytix Biopharma's Partner Verrica Pharmaceuticals to be Presented at SID 2026 Highlight Potential Abscopal Effects of Ruxotemitide in Basal Cell Carcinoma | 19 | Cision News | ||
| 21.04. | Lytix Biopharma ASA to Showcase Promising Phase II Results for Ruxotemitide Combination Therapy at ASCO 2026 | 1 | Cision News | ||
| 21.04. | Lytix Biopharma ASA Reports Promising Final Phase II Results for Ruxotemitide (LTX-315) in Combination with Pembrolizumab in PD-1/PD-L1 Refractory Advanced Melanoma | 7 | Cision News | ||
| 16.04. | Lytix Biopharma ASA - Conversion to public limited liability company and name change registered | 1 | Cision News | ||
| 14.04. | Lytix Biopharma AS: Minutes from Annual General Meeting | 1 | Cision News | ||
| 09.04. | Lytix Biopharma AS: MANDATORY NOTIFICATION OF TRADE BY PRIMARY INSIDER - GRANT OF SHARE OPTIONS | 1 | Cision News | ||
| 07.04. | Lytix Biopharma Names Renée Christine Amundsen COO With Immediate Effect | 1 | RTTNews | ||
| 07.04. | LYTIX BIOPHARMA AS: Lytix Biopharma Appoints Renée Christine Amundsen as Chief Operating Officer to Support Next Phase of Growth | 1 | Cision News | ||
| 25.03. | Lytix Biopharma AS: Notice of Annual General Meeting on 14 April 2026 | 6 | Cision News | ||
| 24.03. | Lytix Biopharma AS: Annual Report for 2025 | 2 | Cision News | ||
| 18.03. | LYTIX BIOPHARMA AS: Lytix Biopharma to Present Final Phase II ATLAS-IT-05 Data at the AACR Annual Meeting 2026 | 4 | Cision News | ||
| 24.02. | Lytix Biopharma AS - New share capital registered | 3 | Cision News | ||
| 17.02. | LYTIX BIOPHARMA AS: Lytix Biopharma Publishes Comprehensive Review on the Transformative Potential of Oncolytic Peptides in Leading Cancer Journal (JITC) | 3 | Cision News | ||
| 12.02. | LYTIX BIOPHARMA AS: Lytix Biopharma: Q4 2025 Presentation and Publication of H2 2025 Interim Report | 1 | Cision News | ||
| 05.02. | LYTIX BIOPHARMA AS: Lytix Biopharma: Invitation to Q4 2025 Results Presentation and Publication of H2 2025 Report | 1 | Cision News | ||
| 12.01. | XFRA CAPITAL ADJUSTMENT INFORMATION - 12.01.2026 | 1.292 | Xetra Newsboard | Das Instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG KG NA ON EQUITY wird cum Kapitalmassnahme gehandelt am 12.01.2026 und ex Kapitalmassnahme am 13.01.2026 The instrument PGH DE000A1MMEV4 THE PAYM.GR.HLDG... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| LINEAGE CELL THERAPEUTICS | 1,014 | +4,75 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien | ||
| NOVOGENIA | 6,650 | 0,00 % | EQS-News: Novogenia AG: Darwin AG vollzieht Umfirmierung in Novogenia AG und stärkt damit internationale Positionierung | EQS-News: Novogenia AG
/ Schlagwort(e): Strategische Unternehmensentscheidung
Darwin AG vollzieht Umfirmierung in Novogenia AG und stärkt damit internationale Positionierung
15.07.2026... ► Artikel lesen | |
| CG ONCOLOGY | 70,19 | 0,00 % | ANI Pharmaceuticals, Inc.: ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter | Trial court denied Company's motion for a new trial and judgment as a matter of law for unjust enrichmentANI intends to appeal rulings to the Delaware Supreme Court and continue to seek to recover... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,300 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| APOGEE THERAPEUTICS | 134,12 | -0,02 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| ERASCA | 18,810 | -0,05 % | Erasca closes $632.5 million public stock offering | ||
| TARSUS PHARMACEUTICALS | 56,33 | +0,14 % | Tarsus Pharmaceuticals, Inc: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth | IRVINE, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) today announced that Aziz Mottiwala, Chief Commercial Officer, is departing the Company to pursue a new... ► Artikel lesen | |
| DYNE THERAPEUTICS | 23,455 | +0,02 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD) | - Priority Review granted; PDUFA target action date set for January 21, 2027 - - Submission for Accelerated Approval based on dystrophin as a surrogate endpoint - - In the registrational expansion... ► Artikel lesen | |
| BEAM THERAPEUTICS | 26,310 | -0,08 % | Beam Therapeutics Announces Compelling Updated Clinical Data from the Ongoing Phase 1/2 Trial of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) to Support Advancement to Pivotal Development | Treatment with 60 mg of BEAM-302 Led to Mean Steady-state Total AAT Level of 16.1 µM and All Patients Consistently and Durably Above the 11 µM Protective AAT Threshold with up to 12 Months of Follow-up... ► Artikel lesen | |
| TREVI THERAPEUTICS | 16,765 | -0,03 % | BMO initiates Trevi Therapeutics stock at Outperform, $36 target | ||
| HEMAB THERAPEUTICS | 49,390 | 0,00 % | Hemab präsentiert Phase-2-Daten für Sutacimig und plant Phase-3-Studie | ||
| KYMERA THERAPEUTICS | 111,11 | +0,04 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader | Dr. Laws, former immunology leader at Sanofi, will oversee global development of Kymera's KT-621 program KT-621 parallel Phase 2b trials advancing in AD and asthma, with data expected by year-end... ► Artikel lesen | |
| QIAGEN | 34,980 | -2,89 % | ANALYSE-FLASH: Berenberg senkt Qiagen auf 'Hold' - Ziel runter auf 40 Euro | HAMBURG (dpa-AFX Broker) - Die Privatbank Berenberg hat das Kursziel für Qiagen von 50 auf 40 Euro gesenkt und die Aktien von "Buy" auf "Hold" abgestuft. Analyst Harry Gillis rechnet mit zunehmendem... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 304,26 | -0,06 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| IMMIX BIOPHARMA | 8,800 | 0,00 % | Kehoe Law Firm, P.C.: Immix Biopharma Stock Drops Significantly On News of Chief Medical Officer Arrest - IMMX Investors Encouraged to Contact Kehoe Law Firm, P.C. Regarding Potential Securities Fraud Claims | Philadelphia, Pennsylvania--(Newsfile Corp. - July 20, 2026) - Kehoe Law Firm, P.C. is investigating potential securities fraud claims on behalf of investors of Immix Biopharma, Inc. ("Immix Biopharma")... ► Artikel lesen |
Das Unternehmen LYTIX BIOPHARMA ASA kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +1,25 % bei einem Aktienkurs von 0,812 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LYTIX BIOPHARMA ASA finden Sie auf Wallstreet Online.